← Back to Search

Azole Antifungal

Opelconazole for Pulmonary Aspergillosis

Phase 2

Waitlist Available

Research Sponsored by Pulmocide Ltd

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 12 weeks

Awards & highlights

Study Summary

This trial is testing a drug to see if it can prevent fungal aspergillus infections in the lungs of people who have had a lung transplant.

Eligible Conditions

Pulmonary Aspergillosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants who complete 12 weeks of therapy

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: OpelconazoleExperimental Treatment1 Intervention

14.8 mg opelconazole administered twice daily for 12 weeks

Group II: Standard of Care (SoC)Active Control1 Intervention

Mold-active SoC prophylaxis/pre-emptive therapy

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Opelconazole

2021

Completed Phase 2

~110

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Pulmocide LtdLead Sponsor

9 Previous Clinical Trials

423 Total Patients Enrolled

1 Trials studying Pulmonary Aspergillosis

123 Patients Enrolled for Pulmonary Aspergillosis

Vice President Clinical DevelopmentStudy DirectorPulmocide Ltd

1 Previous Clinical Trials

100 Total Patients Enrolled

Media Library

PC945 (Azole Antifungal) Clinical Trial Eligibility Overview. Trial Name: NCT05037851 — Phase 2

Pulmonary Aspergillosis Research Study Groups: Opelconazole, Standard of Care (SoC)

Pulmonary Aspergillosis Clinical Trial 2023: PC945 Highlights & Side Effects. Trial Name: NCT05037851 — Phase 2

PC945 (Azole Antifungal) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05037851 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What adverse effects have been seen with the use of PC945?

"PC945 is estimated to be a 2 on the safety scale as it has been tested in Phase 2 clinical trials, hence data regarding its efficacy remains absent."

Answered by AI

Is enrollment in this trial currently open?

"Affirmative. Clinicaltrials.gov displays that this clinical research, initially listed on November 19th 2021, is presently recruiting subjects. 17 medical centres will need to receive 100 patients in total for the trial's completion."

Answered by AI

What is the scope of individuals included in this research?

"This medical trial necessitates the recruitment of 100 individuals who meet certain exclusion criteria. Potential participants can access this research at two different sites, located in Saint Louis and Maywood respectively."

Answered by AI

How many medical centers are offering this research study?

"This medical trial is being conducted in 17 different metropolitan areas, including Saint Louis, Maywood and Houston. To reduce the need for travel, interested patients should select their closest site to enroll."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

2021. "A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05037851.